Therapeutic targets of kras in colorectal cancer

Shafia Rahman; Shimon Garrel; Michael Gerber; Radhashree Maitra; Sanjay Goel

doi:10.3390/cancers13246233

Therapeutic targets of kras in colorectal cancer

Shafia Rahman, Shimon Garrel, Michael Gerber, Radhashree Maitra, Sanjay Goel

Research output: Contribution to journal › Review article › peer-review

5 Scopus citations

Abstract

Patients with metastatic colorectal cancer have a 5-year overall survival of less than 10%. Approximately 45% of patients with metastatic colorectal cancer harbor KRAS mutations. These mutations not only carry a predictive role for the absence of response to anti-EGFR therapy, but also have a negative prognostic impact on the overall survival. There is a growing unmet need for a personalized therapy approach for patients with KRAS-mutant colorectal cancer. In this article, we focus on the therapeutic strategies targeting KRAS-mutant CRC, while reviewing and elaborating on the discovery and physiology of KRAS.

Original language	English (US)
Article number	6233
Journal	Cancers
Volume	13
Issue number	24
DOIs	https://doi.org/10.3390/cancers13246233
State	Published - Dec 1 2021

Keywords

Colorectal cancer
KRAS mutation
Targeted therapy

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3390/cancers13246233

Cite this

@article{69587eeb674945fb8f23acbbaf4445b9,

title = "Therapeutic targets of kras in colorectal cancer",

abstract = "Patients with metastatic colorectal cancer have a 5-year overall survival of less than 10%. Approximately 45% of patients with metastatic colorectal cancer harbor KRAS mutations. These mutations not only carry a predictive role for the absence of response to anti-EGFR therapy, but also have a negative prognostic impact on the overall survival. There is a growing unmet need for a personalized therapy approach for patients with KRAS-mutant colorectal cancer. In this article, we focus on the therapeutic strategies targeting KRAS-mutant CRC, while reviewing and elaborating on the discovery and physiology of KRAS.",

keywords = "Colorectal cancer, KRAS mutation, Targeted therapy",

author = "Shafia Rahman and Shimon Garrel and Michael Gerber and Radhashree Maitra and Sanjay Goel",

note = "Publisher Copyright: {\textcopyright} 2021 by the authors. Licensee MDPI, Basel, Switzerland.",

year = "2021",

month = dec,

day = "1",

doi = "10.3390/cancers13246233",

language = "English (US)",

volume = "13",

journal = "Cancers",

issn = "2072-6694",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "24",

}

TY - JOUR

T1 - Therapeutic targets of kras in colorectal cancer

AU - Rahman, Shafia

AU - Garrel, Shimon

AU - Gerber, Michael

AU - Maitra, Radhashree

AU - Goel, Sanjay

PY - 2021/12/1

Y1 - 2021/12/1

N2 - Patients with metastatic colorectal cancer have a 5-year overall survival of less than 10%. Approximately 45% of patients with metastatic colorectal cancer harbor KRAS mutations. These mutations not only carry a predictive role for the absence of response to anti-EGFR therapy, but also have a negative prognostic impact on the overall survival. There is a growing unmet need for a personalized therapy approach for patients with KRAS-mutant colorectal cancer. In this article, we focus on the therapeutic strategies targeting KRAS-mutant CRC, while reviewing and elaborating on the discovery and physiology of KRAS.

AB - Patients with metastatic colorectal cancer have a 5-year overall survival of less than 10%. Approximately 45% of patients with metastatic colorectal cancer harbor KRAS mutations. These mutations not only carry a predictive role for the absence of response to anti-EGFR therapy, but also have a negative prognostic impact on the overall survival. There is a growing unmet need for a personalized therapy approach for patients with KRAS-mutant colorectal cancer. In this article, we focus on the therapeutic strategies targeting KRAS-mutant CRC, while reviewing and elaborating on the discovery and physiology of KRAS.

KW - Colorectal cancer

KW - KRAS mutation

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=85120998048&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85120998048&partnerID=8YFLogxK

U2 - 10.3390/cancers13246233

DO - 10.3390/cancers13246233

M3 - Review article

AN - SCOPUS:85120998048

SN - 2072-6694

VL - 13

JO - Cancers

JF - Cancers

IS - 24

M1 - 6233

ER -

Therapeutic targets of kras in colorectal cancer

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this